Table 4 Clinical events at 1- and 4-year follow-up for patients treated with sirolimus-eluting stents or bare-metal stents and either incomplete stent apposition (ISA) or complete stent apposition at follow-up

Events	Sirolimus-eluting stent (n = 180)				Bare-metal stent (n = 145)
Events	ISA	Non- ISA	Relative risk (95% CI)	p Value	ISA	Non-ISA	p Value
No. of patients	45	135			12	133

1-Year clinical event rates
MACE (%)	1 (2.2)	10 (7.4)	0.30 (0.04 to 2.3)	0.30	3 (25.0)	31 (23.3)	1.00
Death (%)	0 (0)	0 (0)		1.00	0 (0)	0 (0)	1.00
Myocardial infarction (%)	1 (2.2)	1 (2.2)		1.00	1 (8.3)	6 (4.5)	0.46
TLR (%)	0 (0)	7 (5.2)		0.19	2 (16.7)	27 (20.3)	1.00
Target vessel failure (%)	1 (2.2)	14 (10.4)	0.21 (0.03 to 2.0)	0.12	2 (16.7)	32 (24.1)	0.73
Subacute stent thrombosis (%)	0 (0)	0 (0)		1.00	0 (0)	0 (0)	1.00
Late stent thrombosis (%)	0 (0)	0 (0)		1.00	0 (0)	0 (0)	1.00

4-Year clinical event rates
MACE (%)	5 (11.1)	22 (16.3)	0.67 (0.27 to 1.69)	0.48	5 (41.7)	36 (27.1)	0.32
Death (%)	1 (2.2)	10 (7.4)	0.30 (0.04 to 2.3)	0.30	1 (8.3)	3 (2.3)	0.29
Cardiac death (%)	1 (2.2)	7 (5.2)	0.43 (0.05 to 3.3)	0.68	1 (8.3)	2 (1.5)	0.23
Myocardial infarction (%)	5 (11.1)	6 (4.4)	2.5 (0.70 to 7.69)	0.15	3 (25.0)	7 (5.3)	0.04
TLR (%)	2 (4.4)	9 (6.7)	0.67 (0.15 to 2.9)	0.73	2 (16.7)	29 (21.8)	1.00
Target vessel failure (%)	3 (6.7)	25 (18.5)	0.36 (0.11 to 1.2)	0.06	3 (25.0)	36 (27.1)	1.00
Late stent thrombosis (%)	1 (2.2)	0 (0)		0.25	0 (0)	0 (0)	1.00

CI, confidence interval; MACE, major adverse cardiac events; TLR, target lesion revascularisation.